Method for determining the stage of ulcerative colitis or interstitial pneumonitis and reagent kit thereof
View Patent ↗The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of and the remission phase of ulcerative colitis. The method also measures the value of the PGE-MUM concentration in urine and judges stages between the active phase and the non-active phase of interstitial pneumonitis.
1. A method for judging stages between a pre-remission phase and a remission phase of ulcerative colitis, the method comprising:
setting a base value of a main metabolite of prostaglandin, 7α-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid (PGE-MUM), concentration in urine obtained by measuring PGE-MUM comprised in the urine of patients diagnosed as being in the remission phase of ulcerative colitis under a therapeutic control with the administration of anti-inflammatory drugs; and
judging that ulcerative colitis is in the pre-remission phase when the value of PGE-MUM concentration in urine of the patients is in a range exceeding the base value and being not more than 3 times the base value, and that ulcerative colitis is in the remission phase when the value of PGE-MUM concentration in urine of the patients is in a range of not more than the base value.
2. The method for judging stages according to claim 1 , wherein the pre-remission phase of ulcerative colitis is set as a case when pathological scores (Matts classification) of ulcerative colitis are in a range of 2-3, and the remission phase of ulcerative colitis is set as a case when the pathological scores (Matts classification) of ulcerative colitis are in a range of less than 2.
3. The method of claim 1 , wherein the PGE-MUM concentration in the urine is measured by HPLC.
4. The method of claim 1 , wherein the PGE-MUM concentration in the urine is measured by GC-MS.
5. The method of claim 1 , wherein the PGE-MUM concentration in the urine is measured by immunoassay.
6. The method of claim 5 , wherein the immunoassay comprises an anti-PGE-MUM antibody.
7. The method of claim 6 , wherein the anti-PGE-MUM antibody is a polyclonal antibody.
8. The method of claim 6 , wherein the anti-PGE-MUM antibody is a monoclonal antibody.
9. The method of claim 6 , wherein the immunoassay further comprises a labeled PGE-MUM reagent.
10. The method of claim 2 , wherein the PGE-MUM concentration in the urine is measured by HPLC.
11. The method of claim 2 , wherein the PGE-MUM concentration in the urine is measured by GC-MS.
12. The method of claim 2 , wherein the PGE-MUM concentration in the urine is measured by immunoassay.
13. The method of claim 12 , wherein the immunoassay comprises an anti-PGE-MUM antibody.
14. The method of claim 13 , wherein the anti-PGE-MUM antibody is a polyclonal antibody.
15. The method of claim 13 , wherein the anti-PGE-MUM antibody is a monoclonal antibody.
16. The method of claim 13 , wherein the immunoassay further comprises a labeled PGE-MUM reagent.